ストックスクリーナーアプリを入手
0.4989
1.40%
-0.0009
前日終値:
$0.4998
開ける：
$0.4957
24時間の取引高:
345.78K
Relative Volume:
0.18
時価総額：
$113.86M
収益：
$9.10M
当期純損益:
$-82.47M
株価収益率:
-0.8602
EPS:
-0.58
ネットキャッシュフロー:
$-72.32M
1週間 パフォーマンス:
+18.60%
1か月 パフォーマンス:
+43.30%
6か月 パフォーマンス:
-18.92%
1年 パフォーマンス:
-45.04%
1日の値動き範囲:
$0.48
$0.4999
1週間の範囲:
$0.39
$0.54
52週間の値動き範囲:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
名前
Vaxart Inc
セクター
電話
(650) 550-3500
住所
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
VXRT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.4989 | 92.43M | 9.10M | -82.47M | -72.32M | -0.58 |
|
ONC
Beigene Ltd Adr
|
236.55 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.37 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.07 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.23 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-15 | 開始されました | Oppenheimer | Outperform |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-29 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | 開始されました | Jefferies | Buy |
| 2021-06-11 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-13 | 開始されました | B. Riley FBR | Buy |
すべてを表示
Vaxart Inc (VXRT) 最新ニュース
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Makes Last-Minute Changes to Reverse Split PlanCritical Nasdaq Deadline Approaches - Stock Titan
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart (VXRT) Secures BARDA Approval for Next Phase of COVID-19 Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Receives BARDA Approval for Phase 2b Trial - TipRanks
Vaxart gets nod to expand COVID-19 pill vaccine trial - Investing.com Australia
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Revolutionary Oral COVID Pill Vaccine Gets $460M BARDA Backing for Massive 10,000-Patient Trial - Stock Titan
Vaxart (VXRT) Rises After Positive Trial Results for Norovirus V - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Vaxart (VXRT) Unveils Promising Results from Phase 2b Norovirus Vaccine Study | VXRT Stock News - GuruFocus
Vaxart (VXRT) Appoints New CFO Amid Leadership Change | VXRT Sto - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine - The Manila Times
Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial - Stock Titan
Vaxart, Inc. (NASDAQ:VXRT) Q1 2025 Earnings Call Transcript - Insider Monkey
Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges - Yahoo Finance
Vaxart Inc Q1 2025 Earnings: EPS of -$0.10 and Revenue of $9.55 Million Meet Estimates - GuruFocus
Vaxart Reports Q1 2025 Progress and Financials - TipRanks
Vaxart (VXRT) Advances COVID-19 and Norovirus Vaccine Trials - GuruFocus
Vaxart Q1 2025 Earnings Call Transcript - MarketBeat
Vaxart Q1 Net Loss Narrows, Revenue Rises; Jeroen Grasman Named CFO - marketscreener.com
Vaxart Appoints Jeroen Grasman as New CFO - TipRanks
Vaxart Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxart appoints Jeroen Grasman as new CFO - Investing.com Australia
Vaxart appoints Jeroen Grasman as new CFO By Investing.com - Investing.com Nigeria
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Vaxart, Inc. SEC 10-Q Report - TradingView
Vaxart Unlocks $460M COVID Vaccine Trial Funding, Reports Strong Pipeline Progress in Q1 2025 - Stock Titan
Vaxart Appoints Jeroen Grasman as Chief Financial Officer - GlobeNewswire
Vaxart (VXRT) Proposes Reverse Stock Split to Maintain Nasdaq Li - GuruFocus
Vaxart Proposes Reverse Stock Split to Avoid Delisting - TipRanks
Vaxart, Inc. Encourages Stockholders to Approve Reverse Stock Split Proposal to Maintain Nasdaq Listing - Nasdaq
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement - GlobeNewswire
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart seeks stockholder approval for reverse split By Investing.com - Investing.com Australia
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
Vaxart Inc (VXRT) 財務データ
収益
当期純利益
現金流量
EPS
1.55%
3.00%
大文字化:
|
ボリューム (24 時間):